Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
2007 1
2008 3
2009 3
2010 2
2011 4
2012 4
2013 4
2014 2
2015 2
2016 4
2017 1
2018 5
2019 13
2020 15
2021 11
2022 9
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Adams D, et al. Among authors: gonzalez duarte a. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153. N Engl J Med. 2018. PMID: 29972753 Free article. Clinical Trial.
II. THE RESEARCH ETHICS INVOLVING VULNERABLE GROUPS.
González-Duarte A, Zambrano-González E, Medina-Franco H, Alberú-Gómez J, Durand-Carbajal M, Hinojosa CA, Aguilar-Salinas CA, Kaufer-Horwitz M. González-Duarte A, et al. Rev Invest Clin. 2019;71(4):217-225. doi: 10.24875/RIC.19002812. Rev Invest Clin. 2019. PMID: 31448777 Free article.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Among authors: gonzalez duarte a. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Clinical Trial.
Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City.
Flores-Silva FD, García-Grimshaw M, Valdés-Ferrer SI, Vigueras-Hernández AP, Domínguez-Moreno R, Tristán-Samaniego DP, Michel-Chávez A, González-Duarte A, Vega-Boada FA, Reyes-Melo I, Jiménez-Ruiz A, Chávez-Martínez OA, Rebolledo-García D, Marché-Fernández OA, Sánchez-Torres S, García-Ramos G, Cantú-Brito C, Chiquete E. Flores-Silva FD, et al. Among authors: gonzalez duarte a. PLoS One. 2021 Apr 8;16(4):e0247433. doi: 10.1371/journal.pone.0247433. eCollection 2021. PLoS One. 2021. PMID: 33831042 Free PMC article. Clinical Trial.
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Solomon SD, et al. Among authors: gonzalez duarte a. Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831. Circulation. 2019. PMID: 30586695 Clinical Trial.
Familial dysautonomia.
González-Duarte A, Cotrina-Vidal M, Kaufmann H, Norcliffe-Kaufmann L. González-Duarte A, et al. Clin Auton Res. 2023 May 19. doi: 10.1007/s10286-023-00941-1. Online ahead of print. Clin Auton Res. 2023. PMID: 37204536 Review.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Among authors: gonzalez duarte a. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
AUTHOR'S REPLY.
González-Duarte A. González-Duarte A. Rev Invest Clin. 2020;72(4):260. doi: 10.24875/RIC.M20000003. Rev Invest Clin. 2020. PMID: 33064713 No abstract available.
Early autonomic biomarkers in ATTRv carriers.
González-Duarte A, Norcliffe-Kauffman L. González-Duarte A, et al. Clin Auton Res. 2023 Feb;33(1):9-10. doi: 10.1007/s10286-023-00926-0. Epub 2023 Jan 31. Clin Auton Res. 2023. PMID: 36719509 No abstract available.
82 results